- Home
- RLTY vs SERA Comparison
RLTY vs SERA Comparison
Compare RLTY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | SERA |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 75.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLTY | SERA |
|---|---|---|
| Price | $15.67 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.0K | ★ 36.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $14.04 | $1.37 |
| 52 Week High | $15.97 | $4.09 |
Technical Indicators
Market Signals| Indicator | RLTY | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 42.49 |
| Support Level | $14.93 | N/A |
| Resistance Level | $15.75 | $2.41 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 55.22 | 33.90 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.